Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rubella vaccine
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
The live attenuated rubella vaccine, distributed by **Keymen İlaç** (a subsidiary of **Alagöz Holding**), is a viral vaccine indicated for active immunization against rubella (German measles). It contains a weakened (attenuated) strain of the rubella virus that stimulates the host's immune system to produce specific neutralizing antibodies and cell-mediated immunity. This protection is critical for preventing rubella infection and the associated risk of congenital rubella syndrome (CRS) in infants born to infected mothers. The vaccine is part of Keymen İlaç's portfolio of essential vaccines approved for use in the Turkish market and is typically administered to children and women of childbearing age.
- Brand names
- Kızamıkçık Aşısı
- Other names
- live attenuated rubella vaccineRubella Vaccine
Beyond the preview
Go deeper on rubella vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rubella vaccine.